-
Join 357 other subscribers
Blogroll
HIV/AIDS networks
Links
- bilaterals.org
- Fix the Patent Laws!
- FTA Malaysia
- HAI Europe
- Health Action International (HAI)
- Intellectual Property Watch
- Lawyers Collective HIV/AIDS
- MSF Access Campaign
- Patent Opposition Database
- Public Citizen
- Stop EU-India FTA
- Stop Peru FTA
- Third World Network
- Treatment Action Group
- UAEM Europe
- UAEM evidence collection
- Universities Allied for Essential Medicines (UAEM)
Archives
-
Recent Posts
- Clamour against United Kingdom’s free-trade negotiator
- India, EU conclude another round of talks for proposed trade agreement
- Next round of India, UK talks for free trade agreement to be held in March
- ‘Playing with the lives of HIV patients’: Drug shortages force many to change medication regime
- Pfizer’s Covid pill Paxlovid gets WHO’s approval. All you need to know
Categories
Category Archives: Delinkage
Transparency and delinkage embedded into draft UN Political Declaration on Universal Health Coverage
Source: Keionline 5th August, 2019 UPDATE: On 29 July 2019, the co-facilitators (Ambassadors of Georgia and Thailand) of the intergovernmental consultations on a UN political declaration on universal health coverage announced that the silence procedure was broken by “several delegations … Continue reading
“Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council
Source: Health Policy Watch 9th July, 2019 Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged … Continue reading
Posted in Delinkage, Patent, R&D, Uncategorized
Leave a comment
Indian Civil Society letter on TB Declaration negotiations -UN High Level Meeting
To, Mr. Narendra Modi, Prime Minister of India Mr. J. P. Nadda, Health Minister Ms. Sushma Swaraj, Foreign Minister Mr. Suresh Prabhu, Commerce Minister Date: 31st July 2018 Sub: Asking India to support TRIPS flexibilities in UN High Level Meeting on TB … Continue reading
Draft TB declaration: US, EU push against funding, delinkage pledges
Source: POLITICO PRO| June 12, 2018 The EU and U.S. are resisting concrete commitments on new funding for tuberculosis ahead of a high-level U.N. meeting about fighting the world’s top infectious killer. The two regions are also pushing to eliminate language … Continue reading
Posted in Delinkage, Tuberculosis (TB)
Leave a comment
Stakeholder Intervention at 19th RCEP negotiations round- James Love, Knowledge Ecology International
These are the notes I used when providing the KEI comments at the July 25, 2017 civil society stakeholder forum at the 19th round of the RCEP negotiation. My name is James Love. I work for Knowledge Ecology International, an … Continue reading
Lexmark: The Supreme Court’s patent exhaustion case and parallel trade in drugs
Source: Knowledge Ecology International The Supreme Court’s decision in IMPRESSION PRODUCTS, INC. v. LEXMARK INTERNATIONAL, INC. has clarified that the United States has world wide exhaustion of patent rights. According to Professor Fred Abbott, who knows a lot about this issue, and … Continue reading
Posted in Cancer, Delinkage, ISDS, R&D, Uncategorized, USFDA
Leave a comment
Better life through medicine—let’s leave no one behind
Source: http://www.thelancet.com The Lancet Commission on Essential Medicines Policies rightfully addresses the need to guarantee access to essential medicines for all. However, we cannot achieve any real progress without acknowledging that the current patent-based business model and the way we … Continue reading
Posted in Delinkage, R&D, R&D, Sofosbuvir, TRIPS, TRIPS flexibilities, Uncategorized
Leave a comment
UN High Level Panel report is good prescription for change in access to medicines
Source: PharmaLetter | October 18, 2016 In our weekly expert view piece, Rohit Malpani, director of policy and analysis for Mèdecins Sans Frontiéres Access Campaign, discusses the UN Secretary General’s High-Level Panel report on Access to Medicines and looks at the … Continue reading
Posted in Delinkage, R&D, TPP, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized
Leave a comment
Pay big pharma to solve antibiotics crisis, says UK government review
The Guardian; Pharmaceutical companies should be given cash incentives of up to $3bn to find and develop new antibiotics desperately needed to keep infections at bay, according to a UK government review. Jim O’Neill, the economist and former chair of … Continue reading
Posted in Antibiotics, Delinkage, Innovation
Leave a comment
Talking drug prices #6: Openness vs. secrecy in drug development
Plos Blogs. October 22, 2015. By Mat Todd Contributors in this series on drug prices and access to medicines have mentioned important issues related to policy, finance and intellectual property. I’d like to make a few comments from the point of view … Continue reading
Posted in Delinkage, Innovation, Open access, Pricing
Leave a comment